EGFR and head and neck squamous cell carcinoma: With the hope of identifying novel dual‐therapies and deepening our understanding of the critical factors mediating EGFR inhibitor resistance in HNSCC, we utilized a small molecule profiling strategy to test a library of small molecule inhibitors as monotherapies and in combination with EGFR inhibitors (Figure 1A).